Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unapproved Indications Guidance Proves Controversial

Executive Summary

US FDA has collected more than 100 comments on a pair of draft guidance documents about manufacturer speech relating to unapproved devices or information not listed in device labeling. A document allowing manufacturers to disseminate some information not in the labeling drew fire from both sides, with patient groups worrying the change could pose a risk to the public, while trade groups saying the communication protections were still too narrow.

You may also be interested in...

Talking To Payers: Advancing Bill Would Broaden What Firms Can Say About Investigational Products

The US House Energy and Commerce Health Subcommittee advanced a Republican-sponsored bill that would permit communications between manufacturers and private and public insurers about the benefits of unapproved devices and drugs. Democrats on the panel expressed strong reservations that FDA may feel unduly pressured by insurers to rush through product approvals.

Experts Expect More Speech Protections From FDA During Trump Admin

The ongoing push for less US FDA regulation of speech that is truthful and not misleading should continue through the next several years, experts say.

Congress Must Handle Off-Label Talk Restrictions Carefully, Experts Tell Lawmakers

Two House Energy & Commerce Committee members have introduced legislation to provide clarity and more latitude in off-label communications by manufacturers about devices and drugs, and a panel of legal experts and physicians provided feedback on the topic to the committee's Health subpanel July 12.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts